ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Special Reports

India pharma quality lapses force U.S. to look to China for vital drugs

Toxic medications, burned records, analog systems dim prospects for world's third largest pharmacy

Capsules arranged at Glenmark R&D center in Mumbai, India.    © Getty Images

In the final weeks of 2022, a small team of inspectors from the U.S. Food and Drug Administration were far from home, investigating a pharmaceutical factory in western India.

Indian drugmaker Intas was making cancer drugs for the United States at the plant where, in a trash bin, inspectors found documents doused in acetic acid. More papers with manufacturing and drug testing data were shredded and tucked away in plastic bags under a stairwell, indicating that Intas executives had manipulated data and tried to cover it up.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more